Cargando…
The potential price and access implications of the cost-utility and budget impact methodologies applied by NICE in England and ICER in the US for a novel gene therapy in Parkinson’s disease
Background: NICE in England, and ICER in the US both use cost-utility analyses (CUA) and budget impact analyses (BIA) to assess value for money and affordability, however the thresholds used differ greatly. Objective: To perform a cross-country comparison of the results of the CUA and BIA and detail...
Autores principales: | Jørgensen, Jesper, Servos, Spiros, Kefalas, Panos |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Routledge
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198614/ https://www.ncbi.nlm.nih.gov/pubmed/30364868 http://dx.doi.org/10.1080/20016689.2018.1500419 |
Ejemplares similares
-
Annuity payments can increase patient access to innovative cell and gene therapies under England’s net budget impact test
por: Jørgensen, Jesper, et al.
Publicado: (2017) -
A price comparison of recently launched proprietary pharmaceuticals in the UK and the US
por: Jørgensen, Jesper, et al.
Publicado: (2016) -
HTA’d in the USA: A Comparison of ICER in the United States with NICE in England and Wales
por: Thokala, Praveen, et al.
Publicado: (2020) -
Upgrading the SACT dataset and EBMT registry to enable outcomes-based reimbursement in oncology in England: a gap analysis and top-level cost estimate
por: Jørgensen, Jesper, et al.
Publicado: (2019) -
ICER update to pricing models of remdesivir for COVID-19
Publicado: (2020)